Investors

News Releases

Oct 15, 2020

Evofem Biosciences Secures $25 Million Strategic Investment from Adjuvant Capital
Oct 7, 2020

Evofem Biosciences Announces Presentations on Phexxi and EVO100 at Key Medical Society Meetings
Sep 16, 2020

Evofem Biosciences Announces Updated Date and Time for Fireside Chat at Cantor Global Virtual Healthcare Conference
- Photos 1
Sep 14, 2020

Evofem Biosciences to Present Data at the 2020 STD Prevention Virtual Conference from Phase 2b Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women

- Company plans to initiate Phase 3 STI trial by the end of 2020 -
Sep 8, 2020

Evofem Biosciences Announces U.S. Commercial Launch of Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal, On-Demand Prescription Contraceptive Vaginal Gel

- A First-in-Class Vaginal pH Modulator Designed for Use "In-the-Moment" -
Aug 31, 2020

Evofem Biosciences to Participate in Four Upcoming Investor Conferences
Aug 21, 2020

Evofem Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 4, 2020

Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

- Advancing Precommercial Activities in Preparation for Phexxi™ Commercial Launch in September 2020 -
Aug 3, 2020

Evofem Biosciences' CEO Saundra Pelletier Named to PharmaVOICE100 - The Most Inspiring People in Life Sciences
Jul 23, 2020

Evofem Biosciences to Report Second Quarter 2020 Results and Provide Corporate Update on Tuesday, August 4, 2020

-- Conference Call Scheduled for 11:00 a.m. EDT --

Show per page